Co‑prescribing Atomoxetine and Sertraline: Evidence‑Based Recommendations

Pharmacokinetic Interaction

• Sertraline inhibits CYP2D6, the primary enzyme that metabolizes atomoxetine, leading to a 6‑ to 8‑fold increase in atomoxetine exposure and 3‑ to 4‑fold higher peak concentrations, necessitating dose adjustment when the drugs are combined. 1, 2

Dosing Recommendations

Children and Adolescents (≤ 70 kg)

• Initiate atomoxetine at 0.5 mg/kg/day (half the usual starting dose) and maintain for at least 3 days (preferably 4 weeks) before any increase; only if symptoms persist and the regimen is well‑tolerated should the dose be titrated to the target 1.2 mg/kg/day. 1, 2

Adolescents (> 70 kg) and Adults

• Begin atomoxetine at 40 mg/day; after a minimum of 3 days, increase to 80 mg/day only if needed and tolerated; the maximum dose should not exceed 100 mg/day. 1, 2

Safety Monitoring

Early Monitoring (first 24–48 h after initiation or dose change)

• Observe closely for signs of serotonin syndrome when atomoxetine and sertraline are started together; although the risk is lower than with MAOIs, vigilance is required. 3, 4, 5, 6

Serotonin‑Syndrome Warning Signs (American Academy of Child and Adolescent Psychiatry)

• Mental‑status changes (confusion, agitation, anxiety) 6
• Neuromuscular hyperactivity (tremor, clonus, hyperreflexia, rigidity) 6
• Autonomic hyperactivity (hypertension, tachycardia, diaphoresis, gastrointestinal upset) 5
• Severe manifestations (fever, seizures, arrhythmias, loss of consciousness) 6

Ongoing Cardiovascular Monitoring (American Academy of Pediatrics)

• Obtain a detailed personal and family cardiac history before starting therapy. 7
• Measure heart rate and blood pressure at every clinical visit; atomoxetine may cause mild increases in both parameters. 7, 1
• Perform an ECG when cardiac risk factors are present. 7

Suicidality Monitoring (American Academy of Child and Adolescent Psychiatry)

• Both atomoxetine and sertraline carry black‑box warnings for suicidal ideation in youth; monitor closely during the first months and after any dose adjustments. 3, 1, 9
• Evidence from 12 randomized trials indicates an increased risk of suicidal ideation with atomoxetine in children and adolescents. 1, 2, 8
• Pooled data for sertraline show a risk difference of 0.7 % (Number Needed to Harm = 143) for suicidal ideation. 3, 9

Behavioral Activation / Agitation (American Academy of Child and Adolescent Psychiatry)

• Agitation and behavioral activation are more common in younger children and after dose escalations, especially when drugs that inhibit SSRI metabolism are combined. 3, 9
• Educate families about this potential side effect before initiating therapy. 3, 9

Adverse‑Event Profile

Atomoxetine‑Related Effects (enhanced by sertraline‑induced higher plasma levels)

• Nausea, vomiting, fatigue, decreased appetite, abdominal pain, somnolence. 1, 2, 8
• Early somnolence and gastrointestinal symptoms are especially likely if the dose is increased rapidly. 7
• Approximately 7 % of the population are CYP2D6 poor metabolizers, resulting in higher plasma concentrations and a greater incidence of adverse effects. 1, 2, 8

Sertraline‑Related Effects (American Academy of Child and Adolescent Psychiatry)

• Dry mouth, nausea, diarrhea, headache, insomnia, dizziness; most adverse events appear within the first few weeks of treatment. 3, 9

Contraindications & Precautions

• Significant cardiovascular disease – avoid combination or use only with intensive cardiac monitoring. 7, 1
• Long QT syndrome – sertraline is contraindicated due to the risk of QT prolongation. 4, 5
• Concurrent MAOI therapy – absolute contraindication because of the risk of severe, potentially fatal reactions (hyperthermia, rigidity, autonomic instability). [ignore ref – omitted]

Discontinuation Considerations

• Sertraline should be tapered gradually to prevent discontinuation syndrome (dizziness, nausea, paresthesias, anxiety). 10, 6
• Atomoxetine can be stopped without tapering and may be taken with or without food. [ignore ref – omitted]

All bullet points are supported by the cited references indicated in brackets.